BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company specializing in the development and commercialization of targeted therapies for rare genetic diseases. Founded in 1997 and headquartered in San Rafael, California, the biopharmaceutical manufacturer focuses on addressing severe genetically defined conditions with limited treatment options. BioMarin offers commercialized biopharmaceuticals including Voxzogo for achondroplasia, Palynziq and Kuvan for phenylketonuria, Brineura for Batten disease, and Vimizim, Naglazyme, and Aldurazyme for mucopolysaccharidosis disorders. The company's scientific focus encompasses enzyme replacement therapies, small molecule therapeutics, and advanced gene therapy platforms for conditions like severe hemophilia A. Operating in over 80 countries, BioMarin maintains global research, clinical development, and biologics manufacturing facilities in Novato, California, and Shanbally, Ireland. Through dedicated patient support programs such as BioMarin RareConnections, the company assists healthcare providers, patients, and families throughout treatment journeys. BioMarin continually expands its clinical pipeline to advance groundbreaking therapies for rare metabolic, lysosomal storage, and skeletal dysplasias globally.